Development of a vectored vaccine against hepatitis E virus

scientific article published on 26 February 2014

Development of a vectored vaccine against hepatitis E virus is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.VACCINE.2014.02.041
P698PubMed publication ID24583005
P5875ResearchGate publication ID260444891

P2093author name stringAmine Kamen
Héla Kallel
Khaled Trabelsi
P2860cites workHepatitis E virus (HEV): molecular cloning and sequencing of the full-length viral genomeQ33415661
A rapid method for titrating baculovirus stocks using the Sf-9 Easy Titer cell lineQ33512096
Hepatitis E vaccineQ37278231
Hepatitis E: Historical, contemporary and future perspectivesQ37825651
Production of adeno-associated viral vectors in insect cells using triple infection: optimization of baculovirus concentration ratios.Q40235892
Quantitation of baculovirus particles by flow cytometryQ40701980
Titration of non-occluded baculovirus using a cell viability assayQ44338255
Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trialQ45189946
P433issue24
P407language of work or nameEnglishQ1860
P921main subjecthepatitis EQ326643
vector-borne diseaseQ2083837
hepatitis E virusQ5731737
P1104number of pages4
P304page(s)2808-2811
P577publication date2014-02-26
P1433published inVaccineQ7907941
P1476titleDevelopment of a vectored vaccine against hepatitis E virus
P478volume32

Reverse relations

cites work (P2860)
Q56588500Development of new hepatitis E vaccines
Q54254955Hepatitis E: Update on Prevention and Control.
Q47159881Public health risks associated with hepatitis E virus (HEV) as a food‐borne pathogen
Q36756695Serotype-specific Binding Properties and Nanoparticle Characteristics Contribute to the Immunogenicity of rAAV1 Vectors